Corporate Japan's Shareholders Show More Clout This AGM Season
While shareholders in general still support company management, the notable break from their passive stance is seen as a boon for funds looking to invest in Japan. Activist investors have been inundating companies with an unprecedented number of proposals at meetings, calling for action such as the disposal of real estate, changes in strategy and bigger stock buybacks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
If You Bought Only 1 Share of Nvidia at Its IPO, Here's How Many Shares You'd Own Now
Key Points Nvidia's initial public offering (IPO) was on January 22, 1999. The company has executed six stock splits in its 26 years as a public company. Investors who held on to just one share from the IPO would have seen over $85,000 in gains. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has dominated stock market discussion over the past couple years, but it's far from a newcomer. The company was founded on April 5, 1993, and it began trading publicly after its initial public offering (IPO) on January 22, 1999. Had you bought one share of Nvidia stock at its IPO, you would currently have 480 shares, thanks to the six stock splits it has undergone in that time. Stock-Split Date Amount of the Stock Split June 2000 2-for-1 Sept. 2001 2-for-1 April 2006 2-for-1 Sept. 2007 3-for-2 July 2021 4-for-1 June 2024 10-for-1 Data source: Seeking Alpha. How much money would you have made in that time? Although Nvidia has been on the market for a quarter century, it hasn't always been the high-flying stock that investors have seen over the past few years. That said, had you bought one share of Nvidia at its IPO price of $12.00 per share and held on to it all this time, your investment would be worth $85,378 as of this writing. That works out to just under a 40% compound annual growth rate for your position. It's also worth noting that this rate of return doesn't include Nvidia's dividend, which it initiated in Nov. 2012. Anyone who reinvested their dividends would only have boosted their long-term returns. These are mind-boggling results, and Nvidia seems to have plenty left in the tank as it takes center stage in the growth of artificial intelligence. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. If You Bought Only 1 Share of Nvidia at Its IPO, Here's How Many Shares You'd Own Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Nektar Therapeutics (NASDAQ:NKTR) should be aware of the most powerful shareholder groups. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Nektar Therapeutics, beginning with the chart below. Check out our latest analysis for Nektar Therapeutics What Does The Institutional Ownership Tell Us About Nektar Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Nektar Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nektar Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Nektar Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Charles Schwab Investment Management, Inc. is the largest shareholder with 8.3% of shares outstanding. BVF Partners L.P. is the second largest shareholder owning 7.4% of common stock, and Millennium Management LLC holds about 5.4% of the company stock. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Nektar Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Nektar Therapeutics in their own names. It has a market capitalization of just US$397m, and the board has only US$4.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. General Public Ownership With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Nektar Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Nektar Therapeutics has 4 warning signs (and 3 which can't be ignored) we think you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
42 minutes ago
- Bloomberg
Bond Market's Pain Trade Turns to Payoff on Jobs Shock
Just when bond investors were doubting one of their favorite strategies, it's making a comeback. Treasuries surged on Friday as a surprisingly weak US payroll report unleashed a frenzy of buying following a month of bond losses. The data, including downward revisions that trimmed a whopping 258,000 jobs from the tallies in May and June, sent traders piling into fresh wagers on Federal Reserve interest-rate cuts, with futures pricing in 84% odds of a reduction next month and at least two cuts by year-end.
